Other actions have been filed making similar allegations regarding the IPOs of more than 300 other companies. All of these have been coordinated for pretrial purposes as In re Initial Public Offering Securities Litigation, Civil Action No. 21-MC-92.

The original complaint was filed alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. On or about March 9, 2000, OraPharma commenced an initial public offering of 4,000,000 of its shares of common stock at an offering price of $17 per share (the "OraPharma IPO"). In connection therewith, OraPharma filed a registration statement, which incorporated a prospectus (the "Prospectus"), with the SEC. The complaint further alleges that the Prospectus was materially false and misleading because it failed to disclose, among other things, that: (i) the Underwriters had solicited and received excessive and undisclosed commissions from certain investors in exchange for which the Underwriters allocated to those investors material portions of the restricted number of OraPharma shares issued in connection with the OraPharma IPO; and (ii) the Underwriters had entered into agreements with customers whereby the Underwriters agreed to allocate OraPharma shares to those customers in the OraPharma IPO in exchange for which the customers agreed to purchase additional OraPharma shares in the aftermarket at pre-determined prices.